Related Experiment Video
Updated: Sep 6, 2025
Generation of a Chronic Obstructive Pulmonary Disease Model in Mice by Repeated Ozone Exposure
Published on: August 25, 2017
Advances and applications of monoolein as a novel nanomaterial in mitigating chronic lung diseases
Yinghan Chan1, Sachin Kumar Singh2,3, Monica Gulati2,3
1Department of Life Sciences, School of Pharmacy, International Medical University (IMU), Bukit Jalil, 57000, Kuala Lumpur, Malaysia.
Abstract:
Chronic lung diseases such as asthma, chronic obstructive pulmonary disease, lung cancer, and the recently emerged COVID-19, are a huge threat to human health, and among the leading causes of global morbidity and mortality every year. Despite availability of various conventional therapeutics, many patients remain poorly controlled and have a poor quality of life. Furthermore, the treatment and diagnosis of these diseases are becoming increasingly challenging. In the recent years, the application of nanomedicine has become increasingly popular as a novel strategy for diagnosis, treatment, prevention, as well as follow-up of chronic lung diseases. This is attributed to the ability of nanoscale drug carriers to achieve targeted delivery of therapeutic moieties with specificity to diseased site within the lung, thereby enhancing therapeutic outcomes of conventional therapies whilst minimizing the risks of adverse reactions. For this instance, monoolein is a polar lipid nanomaterial best known for its versatility, thermodynamic stability, biocompatibility, and biodegradability. As such, it is commonly employed in liquid crystalline systems for various drug delivery applications. In this review, we present the applications of monoolein as a novel nanomaterial-based strategy for targeted drug delivery with the potential to revolutionize therapeutic approaches in chronic lung diseases.
Insights
Monoolein, a versatile nanomaterial, offers targeted drug delivery for chronic lung diseases like asthma and COPD. This nanomedicine approach enhances treatment efficacy and minimizes side effects for better patient outcomes.
Area of Science:
- Nanomedicine and Drug Delivery
- Pulmonology and Respiratory Medicine
Background:
- Chronic lung diseases (asthma, COPD, lung cancer, COVID-19) pose significant global health challenges.
- Current treatments often result in poor disease control and reduced quality of life.
- Diagnosis and treatment of these conditions are increasingly complex.
Purpose of the Study:
- To review the application of nanomedicine for diagnosing and treating chronic lung diseases.
- To highlight monoolein as a novel nanomaterial for targeted drug delivery in lung diseases.
- To explore the potential of monoolein-based strategies to revolutionize chronic lung disease therapeutics.
Main Methods:
- Review of existing literature on nanomedicine applications in chronic lung diseases.
- Focus on the properties and uses of monoolein in drug delivery systems.
- Analysis of monoolein's role in achieving targeted delivery to lung tissues.
Main Results:
- Nanoscale drug carriers enable targeted delivery to specific sites within the lungs.
- This targeted approach enhances therapeutic outcomes for conventional treatments.
- Monoolein exhibits desirable properties like stability, biocompatibility, and biodegradability for drug delivery.
Conclusions:
- Monoolein is a promising polar lipid nanomaterial for advanced drug delivery systems.
- Its application in liquid crystalline systems can significantly improve chronic lung disease management.
- Monoolein-based nanomedicine holds potential to revolutionize therapeutic strategies for respiratory illnesses.
Related Concept Videos
01:20Chronic Obstructive Pulmonary Disease-I: Introduction
01:20Chronic Obstructive Pulmonary Disease-II: Pathophysiology
Chronic Inflammation
01:20Asthma: Pathogenesis and Management
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
01:19Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers work through two distinct mechanisms:
01:29Chronic Obstructive Pulmonary Disease-V: Management
Smoking Cessation
01:22Chronic Obstructive Pulmonary Disease
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...